United States
Icahn School of Medicine at Mount Sinai Hospital - Department of Pathology
Breast Cancer, ricolinostat, HDAC6, clinical trial, biomarker, c-MYC
triple negative breast cancer, chemoresistance, Single-cell transcriptome, genome-wide CRISPR-Cas9 screening, pseudo-temporal trajectory, afatinib, paclitaxel, doxorubicin